These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36374076)

  • 1. Why Molnupiravir Fails in Hospitalized Patients.
    Brown AN; Lang Y; Zhou J; Franco EJ; Hanrahan KC; Bulitta JB; Drusano GL
    mBio; 2022 Dec; 13(6):e0291622. PubMed ID: 36374076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
    Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
    Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molnupiravir: an antiviral drug against COVID-19.
    Dave B; Shah KC; Chorawala MR; Shah N; Patel P; Patel S; Shah P
    Arch Virol; 2023 Sep; 168(10):252. PubMed ID: 37710056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
    Fischer WA; Eron JJ; Holman W; Cohen MS; Fang L; Szewczyk LJ; Sheahan TP; Baric R; Mollan KR; Wolfe CR; Duke ER; Azizad MM; Borroto-Esoda K; Wohl DA; Coombs RW; James Loftis A; Alabanza P; Lipansky F; Painter WP
    Sci Transl Med; 2022 Jan; 14(628):eabl7430. PubMed ID: 34941423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals.
    Bihorel S; Cao Y; Chawla A; Birger R; Maas BM; Gao W; Roepcke S; Sardella S; Humphrey R; Kondragunta S; Jayaraman B; Martinho M; Painter W; Painter G; Holman W; De Anda C; Brown ML; Johnson MG; Paschke A; Rizk ML; Stone JA
    CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1859-1871. PubMed ID: 37798914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real life experience of molnupiravir as a treatment of SARS-CoV-2 infection in vaccinated and unvaccinated patients: a letter on its effectiveness at preventing hospitalization.
    Scioscia G; De Pace CC; Giganti G; Tondo P; Foschino Barbaro MP; Lacedonia D
    Ir J Med Sci; 2023 Oct; 192(5):2301-2303. PubMed ID: 36454535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review.
    Mali KR; Eerike M; Raj GM; Bisoi D; Priyadarshini R; Ravi G; Chaliserry LF; Janti SS
    Ir J Med Sci; 2023 Aug; 192(4):1665-1678. PubMed ID: 36087236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molnupiravir Revisited-Critical Assessment of Studies in Animal Models of COVID-19.
    Rasmussen HB; Hansen PR
    Viruses; 2023 Oct; 15(11):. PubMed ID: 38005828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molnupiravir Use Among Patients with COVID-19 in Real-World Settings: A Systematic Literature Review.
    Richmond DiBello J; Raziano VT; Liu X; Puenpatom A; Peebles K; Khan NF; Hill DD
    Infect Dis Ther; 2024 Jun; 13(6):1177-1198. PubMed ID: 38743192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters.
    Abdelnabi R; Maes P; de Jonghe S; Weynand B; Neyts J
    Front Pharmacol; 2022; 13():1072202. PubMed ID: 36605401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID-19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic.
    Kikuchi K; Nangaku M; Ryuzaki M; Yamakawa T; Ota Y; Hanafusa N; Sakai K; Kanno Y; Ando R; Shinoda T; Wakino S; Nakamoto H; Takemoto Y; Akizawa T;
    Ther Apher Dial; 2023 Dec; 27(6):1064-1069. PubMed ID: 37395555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virology and safety profile of Molnupiravir at three different doses for treatment of SARS-CoV-2: a systematic review and meta-analysis.
    Sukaina M; Shuja SH; Rehan ST; Ochani S; Sheryar M
    APMIS; 2024 Mar; 132(3):139-151. PubMed ID: 38288881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic strategies for COVID-19: progress and lessons learned.
    Li G; Hilgenfeld R; Whitley R; De Clercq E
    Nat Rev Drug Discov; 2023 Jun; 22(6):449-475. PubMed ID: 37076602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral Treatment of Coronavirus Disease-2019 Pneumonia.
    Radcliffe C; Malinis M; Azar MM
    Clin Chest Med; 2023 Jun; 44(2):279-297. PubMed ID: 37085220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of late-onset antiviral treatment in immune-compromised hosts with persistent SARS-CoV-2 infection.
    Lieber CM; Kang HJ; Sobolik EB; Sticher ZM; Ngo VL; Gewirtz AT; Kolykhalov AA; Natchus MG; Greninger AL; Suthar MS; Plemper RK
    bioRxiv; 2024 May; ():. PubMed ID: 38826222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of molnupiravir in patients with Omicron variant vaccine breakthrough COVID-19 infection: a randomized, controlled trial.
    Liu Y; Fan S; Xu A; Ge L; Wang X; Dong X; Xu M; Fan W; Zhong W; Liang X
    Front Pharmacol; 2023; 14():1197671. PubMed ID: 38034986
    [No Abstract]   [Full Text] [Related]  

  • 17. SARS-CoV-2 infection in solid organ transplant recipients: Experience with molnupiravir.
    Villamarín M; Len O
    Rev Esp Quimioter; 2023 Nov; 36 Suppl 1(Suppl 1):22-24. PubMed ID: 37997866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model.
    Johnson DM; Brasel T; Massey S; Garron T; Grimes M; Smith J; Torres M; Wallace S; Villasante-Tezanos A; Beasley DW; Comer JE
    Antiviral Res; 2023 Jan; 209():105492. PubMed ID: 36535309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molnupiravir: Mechanism of action, clinical, and translational science.
    Maas BM; Strizki J; Miller RR; Kumar S; Brown M; Johnson MG; Cheng M; De Anda C; Rizk ML; Stone JA
    Clin Transl Sci; 2024 Feb; 17(2):e13732. PubMed ID: 38593352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier.
    Chang CH; Peng WY; Lee WH; Lin TY; Yang MH; Dalley JW; Tsai TH
    EBioMedicine; 2023 Sep; 95():104748. PubMed ID: 37544201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.